A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results in a ...
Indian-made Myval and Myval Octacor were put to the test against Sapien 3 in the noninferiority trial COMPARE TAVI-1. Noninferiority was demonstrated when counting deaths, strokes, moderate or severe ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Pi-Cardia received Food and Drug Administration clearance ...
Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut transcatheter aortic valve replacement (TAVR) system in low-risk aortic stenosis ...
Edwards Lifesciences reports strong Q4 2025 results with 13.3% sales growth to $1.57B, driven by TAVR and TMTT performance ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
Investor's Business Daily on MSN
Edwards wavers analysts debate its earnings miss amid hefty TAVR investments
Edwards Lifesciences stock wavered Wednesday, though the heart-valve replacement maker issued a bullish outlook for 2026.
For a balloon-expandable transcatheter aortic valve replacement (TAVR or TAVI) platform, the much-litigated Myval performed well enough in the COMPARE-TAVI 1 randomized trial, but its rates of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results